The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the Advisory Committee on Immunization Practices (ACIP)—whose appointment was ...

Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...

Not long after lending its support to a documentary aimed at shining on light on the often-overlooked stories of women with hemophilia, Sanofi is continuing its film-focused collaboration with patient ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to ...

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...

Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly ...

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. After inking a deal worth up to $690 million to take on worldwide rights to the med last week, the FDA has doled out an ...

In a bid to expand its reach in the attention-deficit/hyperactivity disorder (ADHD) market, Collegium Pharmaceutical has struck a deal to ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in ...

With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...